Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Activity of ex vivo graft and DLI Engineering within the last decade increases, a survey from the EBMT Cellular Therapy & Immunobiology Working Party

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Data availability

The data that support the findings of this study are available from EBMT Cellular Therapy & Immunobiology Working Party but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of EBMT Cellular Therapy & Immunobiology Working Party.


  1. de Witte M, Daenen LGM, van der Wagen L, van Rhenen A, Raymakers R, Westinga K, et al. Allogeneic stem cell transplantation platforms with ex vivo and in vivo immune manipulations: count and adjust. Hemasphere. 2021;5:e580.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Bleakley M, Sehgal A, Seropian S, Biernacki MA, Krakow EF, Dahlberg A, et al. Naive T-cell depletion to prevent chronic graft-versus-host disease. J Clin Oncol. 2022;40:1174–85.

    Article  CAS  PubMed  Google Scholar 

  3. Schmid C, Kuball J, Bug G. Defining the role of donor lymphocyte infusion in high-risk hematologic malignancies. J Clin Oncol. 2021;39:397–418.

  4. Schmid C, Labopin M, Schaap N, Veelken H, Brecht A, Stadler M, et al. Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. Bone Marrow Transpl. 2022;57:215–23.

    Article  CAS  Google Scholar 

  5. Santoro N, Mooyaart JE, Devillier R, Koc Y, Vydra J, Castagna L, et al. Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: a study on behalf of the EBMT cellular therapy & immunobiology working party. Bone Marrow Transpl. 2023;58:54–60.

    Article  CAS  Google Scholar 

  6. Polverelli N, Farina M, D’Adda M, Damiani E, Grazioli L, Leoni A, et al. How we manage myelofibrosis candidates for allogeneic stem cell transplantation. Cells. 2022;11:553.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kohler N, Ruess DA, Kesselring R, Zeiser R. The role of immune checkpoint molecules for relapse after allogeneic hematopoietic cell transplantation. Front Immunol. 2021;12:634435.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Foell J, Schulte JH, Pfirstinger B, Troeger A, Wolff D, Edinger M, et al. Haploidentical CD3 or alpha/beta T-cell depleted HSCT in advanced stage sickle cell disease. Bone Marrow Transpl. 2019;54:1859–67.

    Article  CAS  Google Scholar 

  9. Burns SO, Morris EC. How I use allogeneic HSCT for adults with inborn errors of immunity. Blood. 2021;138:1666–76.

    Article  CAS  PubMed  Google Scholar 

  10. Langenhorst JB, Dorlo TPC, van Maarseveen EM, Nierkens S, Kuball J, Boelens JJ, et al. Population pharmacokinetics of fludarabine in children and adults during conditioning prior to allogeneic hematopoietic cell transplantation. Clin Pharmacokinet. 2019;58:627–37.

  11. Admiraal R, Nierkens S, de Witte MA, Petersen EJ, Fleurke GJ, Verrest L, et al. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis. Lancet Haematol. 2017;4:e183–e91.

    Article  PubMed  Google Scholar 

  12. Tremblay G, Dolph M, Patel S, Brandt P, Forsythe A. Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom. Cost Eff Resour Alloc. 2018;16:33.

    Article  PubMed  PubMed Central  Google Scholar 

Download references


We thank all the participating EBMT affiliated centers listed in Supplementary Material.


Funding for this study was provided by the KWF UU 2015-7553 to MdW; KWF, UU 2018-11393, UU 2018-11979, UU 2020-12586, UU 2021- 13043 to JK and 2021-13493 to MdW and JK.

Author information

Authors and Affiliations



JM and JH collected data. MdW, JM and JK analyzed data. MdW, JM, AR and JK designed the study. MdW, CC, FM, AR, JK wrote the manuscript. All authors approved the final version of the manuscript.

Corresponding author

Correspondence to J. Kuball.

Ethics declarations

Competing interests

JK is inventor on multiple patents dealing with gdTCRs, ligands, isolation strategies of engineered immune cells. JK is cofounder and shareholder of Gadeta ( JK and MdW received research, advisor and clinical study support from Miltenyi Biotech. JK received further research support from Novartis and Gadeta.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information


Supplemental data of ‘Activity of ex vivo graft and DLI Engineering within the last decade increases, a survey from the EBMT Cellular Therapy & Immunobiology Working Party’

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

de Witte, M.A., Mooyaart, J.E., Hoogenboom, J.D. et al. Activity of ex vivo graft and DLI Engineering within the last decade increases, a survey from the EBMT Cellular Therapy & Immunobiology Working Party. Bone Marrow Transplant (2023).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI:


Quick links